



PATENT

Attorney Docket No. IOGEN-08729

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Eakle, *et al.*

Serial No.: 10/764,201

Group No.: 1633

Filed: 1/23/2004

Examiner: Leavitt

Entitled: **ransgenic Animals Expressing Transdominant Negative Retroviral Nucleic Acids and Proteins**

**INFORMATION DISCLOSURE  
STATEMENT TRANSMITTAL**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on October 25, 2006.

By: 

Mary Ellen Waite


Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

A check for \$180.00 is also enclosed pursuant to 37 C.F.R. § 1.17(p) for filing this Information Disclosure Statement after three months as set forth in C.F.R. § 1.97(c).

The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: October 25, 2006

  
Tanya A. Arenson  
Registration No. 47,391

MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 305  
San Francisco, California 94105  
608/218-6900




**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Eakle, *et al.*  
Serial No.: 10/764,201  
Filed: 1/23/2004  
Entitled: **Transgenic Animals Expressing Transdominant Negative Retroviral Nucleic Acids and Proteins**  
Group No.: 1633  
Examiner: Leavitt

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450



Sir or Madam:

The citations listed below may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.


- U.S. Patent No. 5,871,958
- U.S. Patent No. 6,162,898
- EP 0406557
- Pollari, F.L., et al., "Effects of bovine leukemia virus infection on production and reproduction in dairy cattle," Can. J. Vet. Res., 56(4):289-95 (1992)


- Hidaka et al., "Post-transcriptional regulator (rex) of HTLV-1 initiates expression of viral structural proteins but suppresses expression of regulatory proteins," EMBO J 7:519 (1988)
- Malim, M.H., et al., "Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes," Nature, 335:181 (1988)
- Rimsky, L., et al., "Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein," Nature, 335:738 (1988)
- Green, P.L., et al., The Retroviridae, p. 227-311, vol. 3, Eds. Levy, J.A., Plenum Press, New York, N.Y., (1994)
- Ghysdael, K., et al., "Bovine leukemia virus," Current Topics in Microbiology and Immunology 112:1 (1984) Gree, P.L., et al., The Retroviridae, p. 227-311, vol. 3, Eds. Levy, J.A., Plenum Press, New York, N.Y., (1994)
- Orlik, O., and Splitter G.A., "Progression to persistent lymphocytosis and tumor development in bovine leukemia virus (BLV)-infected cattle correlates with impaired proliferation of CD4+ T cells in response to gag- and env-encoded BLV proteins," J. Virol., 70(11):7584 (1996)
- Elovaara, I., et al., "High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease," J. Exp. Med., 177:1567 (1993)
- Lassauzet, ML, et al., "Factors associated with transmission of bovine leukemia virus by contact in cows on a California dairy," Amer. J. Epidemiol, 133:164-76 (1991)
- Lassauzet, M.L., et al., "Effect of brucellosis vaccination and dehorning on transmission of bovine leukemia virus in heifers on a California dairy," Can. J. Vet. Res. 54:184-189 (1990)
- Buxton, B.A., and Schultz, R.D., "Factors affecting the infectivity of lymphocytes from cattle with bovine leukosis virus," Can. J. Comp. Med., 48(4):365-369 (1984)
- Herskowitz, I., Nature 329:317 (1987)

- Hope, I.A., and Struhl, K., "Functional dissection of a eukaryotic transcriptional activator protein, GCN4 of yeast," *Cell* 46:885 (1986)
- Gentz, R., et al., "Parallel association of Fos and Jun leucine zippers juxtaposes DNA binding domains," *Science* 243:1695 (1989)
- Triezenberg, S.J., et al., *Gen. & Devel.*, 2:718 (1988)
- Friedman A.D., et al., "Functional dissection of VP16, the trans-activator of herpes simplex virus immediate early gene expression," *Nature*, 335:452 (1988)
- Wachsman, V., et al., "HTLV x gene mutants exhibit novel transcriptional regulatory phenotypes," *Science* 235:674 (1987)
- Green, M., et al., "Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression," *Cell* 58:215 (1989)
- Trono, D., et al., "HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus," *Cell* 59:113 (1989)
- Orlik, O., and Splitter G.A., "Optimization of lymphocyte proliferation assay for cells with high spontaneous proliferation in vitro: CD4+ T cell proliferation in bovine leukemia virus infected animals with persistent lymphocytosis," *J. Immunol. Methods* 199:159 (1996)
- Kimata, J.J., et al., "The mitogenic activity of human T-cell leukemia virus type I is T-cell associated and requires the CD2/LFA-3 activation pathway," *J. Virol.*, 67:3134 (1993)
- Boris-Lawrie et al., "In vivo study of genetically simplified bovine leukemia virus derivatives that lack tax and rex," *J Virol* 71(2):1514-20 (1997)
- Gatei M.H., et al., "Experimental infection of sheep with bovine leukemia virus: infectivity of blood, nasal and saliva secretions," *Zentralbl Veterinarmed, (B)* 36(9):652-60 (1989)

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: 10/25/06

  
\_\_\_\_\_  
Tanya A. Arenson  
Registration No. 47,391  
MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94105  
608/218-6900



**Complete if Known**

**(Use as many sheets as necessary)**

Sheet	1
-------	---

of	4
----	---

Application Number	10/764,201
Filing Date	1/23/2004
First Named Inventor	Eakle, et al.
Art Unit	1633
Examiner Name	Leavitt
Attorney Docket Number	IOGEN-08729

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	3	EP 0406557	05/23/1990	Bachmayer et al	Whole Document	

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/764,201		
		Filing Date	1/23/2004		
		First Named Inventor	Eakle, et al.		
		Art Unit	1633		
		Examiner Name	Leavitt		
Sheet	2	of	4	Attorney Docket Number	IOGEN-08729

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	4	Pollari, F.L., et al., "Effects of bovine leukemia virus infection on production and reproduction in dairy cattle," Can. J. Vet. Res., 56(4):289-95 (1992)	
	5	Hidaka et al., "Post-transcriptional regulator (rex) of HTLV-1 initiates expression of viral structural proteins but suppresses expression of regulatory proteins," EMBO J 7:519 (1988)	
	6	Malim, M.H., et al., "Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes," Nature, 335:181 (1988)	
	7	Rimsky, L., et al., "Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein," Nature, 335:738 (1988)	
	8	Green, P.L., et al., The Retroviridae, p. 227-311, vol. 3, Eds. Levy, J.A., Plenum Press, New York, N.Y., (1994)	
	9	Ghysdael, K., et al., "Bovine leukemia virus," Current Topics in Microbiology and Immunology 112:1 (1984) Gree, P.L., et al., The Retroviridae, p. 227-311, vol. 3, Eds. Levy, J.A., Plenum Press, New York, N.Y., (1994)	
	10	Orlik, O., and Splitter G.A., "Progression to persistent lymphocytosis and tumor development in bovine leukemia virus (BLV)-infected cattle correlates with impaired proliferation of CD4+ T cells in response to gag- and env-encoded BLV proteins," J. Virol., 70(11):7584 (1996)	
	11	Elovaara, I., et al., "High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease," J. Exp. Med., 177:1567 (1993)	
	12	Lassauzet, ML, et al., "Factors associated with transmission of bovine leukemia virus by contact in cows on a California dairy," Amer. J. Epidemiol, 133:164-76 (1991)	
	13	Lassauzet, M.L., et al., "Effect of brucellosis vaccination and dehorning on transmission of bovine leukemia virus in heifers on a California dairy," Can. J. Vet. Res. 54:184-189 (1990)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/764,201
		Filing Date	1/23/2004
		First Named Inventor	Eakle, et al.
		Art Unit	1633
		Examiner Name	Leavitt
Sheet 3	of 4	Attorney Docket Number IOGEN-08729	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	14	Buxton, B.A., and Schultz, R.D., "Factors affecting the infectivity of lymphocytes from cattle with bovine leukosis virus," Can. J. Comp. Med., 48(4):365-369 (1984)	
	15	Herskowitz, I., Nature 329:317 (1987)	
	16	Hope, I.A., and Struhl, K., "Functional dissection of a eukaryotic transcriptional activator protein, GCN4 of yeast," Cell 46:885 (1986)	
	17	Gentz, R., et al., "Parallel association of Fos and Jun leucine zippers juxtaposes DNA binding domains," Science 243:1695 (1989)	
	18	Triezenberg, S.J., et al., Gen. & Devel., 2:718 (1988)	
	19	Friedman A.D., et al., "Functional dissection of VP16, the trans-activator of herpes simplex virus immediate early gene expression," Nature, 335:452 (1988)	
	20	Wachsman, V., et al., "HTLV x gene mutants exhibit novel transcriptional regulatory phenotypes," Science 235:674 (1987)	
	21	Green, M., et al., "Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression," Cell 58:215 (1989)	
	22	Trono, D., et al., "HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus," Cell 59:113 (1989)	
	23	Orlik, O., and Splitter G.A., "Optimization of lymphocyte proliferation assay for cells with high spontaneous proliferation in vitro: CD4+ T cell proliferation in bovine leukemia virus infected animals with persistent lymphocytosis," J. Immunol. Methods 199:159 (1996)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/764,201
		Filing Date	1/23/2004
		First Named Inventor	Eakle, et al.
		Art Unit	1633
		Examiner Name	Leavitt
Sheet 4	of 4	Attorney Docket Number	IOGEN-08729

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	24	Kimata, J.J., et al., "The mitogenic activity of human T-cell leukemia virus type I is T-cell associated and requires the CD2/LFA-3 activation pathway," J. Virol., 67:3134 (1993)	
	25	Boris-Lawrie et al., "In vivo study of genetically simplified bovine leukemia virus derivatives that lack tax and rex," J Virol 71(2):1514-20 (1997)	
	26	Gatei M.H., et al., "Experimental infection of sheep with bovine leukemia virus: infectivity of blood, nasal and saliva secretions," Zentralbl Veterinarmed, (B) 36(9):652-60 (1989)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.